Market Overview

Vanda Announces Negative Opinion from CHMP on Fanaptum for the Treatment of Schizophrenia

Vanda Pharmaceuticals (NASDAQ: VNDA), announced today that the European Medicines Agency's (EMA) Committee for Medicinal Product for Human Use (CHMP) has issued a negative opinion recommending against approval of Fanaptum (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union.  The CHMP was of the opinion that the benefits of Fanaptumâ„¢ did not outweigh its risks and recommended against marketing authorization at this point in time.  Vanda intends to appeal this opinion and request a re-examination of the decision by the CHMP. 

About Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.  

Company Contact:Cristina MurphySenior Communications Manager Vanda Pharmaceuticals Inc.(202) 734-3414cristina.murphy@vandapharma.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances,

See full press release

Posted-In: Earnings News Guidance Management Global

 

Related Articles (VNDA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters